ClinicalTrials.gov
public full text
Public Domain
Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients
A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma#1008954
- A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers#1032008
- Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens#883137
- Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults#897657
- Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients#853225
Record · ID 1163746
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive